Skip to main navigation Skip to search Skip to main content

Erratum: Impact of the M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir therapy in HIV treatment-experienced patients (Open Forum Infectious Diseases (2019) 6: 10 (ofz330) DOI: 10.1093/ofid/ofz330)

  • Flaminia Olearo
  • , Huyen Nguyen
  • , Fabrice Bonnet
  • , Sabine Yerly
  • , Gilles Wandeler
  • , Marcel Stoeckle
  • , Matthias Cavassini
  • , Alexandra Scherrer
  • , Dominique Costagliola
  • , Patrick Schmid
  • , Huldrych F. Günthard
  • , Enos Bernasconi
  • , J. rg Boeni
  • , Antonella D’Arminio Monforte
  • , Maurizio Zazzi
  • , Barbara Rossetti
  • , Didier Neau
  • , Pantxika Bellecave
  • , Bart Rijnders
  • , Peter Reiss
  • Ferdinand Wit, Roger Kouyos, Alexandra Calmy

Research output: Contribution to journalErratum/CorrigendumAcademic

9 Downloads (Pure)

Abstract

In “Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients” Open Forum Infectious Diseases, Volume 6, Issue 10, October 2019, ofz330, https://doi.org/10.1093/ofid/ofz330, the surname of a co-author, Dominique Costagliola, was misspelled. This was corrected in the new version of the manuscript.
Original languageEnglish
JournalOpen forum infectious diseases
Volume6
Issue number12
DOIs
Publication statusPublished - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Erratum: Impact of the M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir therapy in HIV treatment-experienced patients (Open Forum Infectious Diseases (2019) 6: 10 (ofz330) DOI: 10.1093/ofid/ofz330)'. Together they form a unique fingerprint.

Cite this